Nieves Martinez Lago MD PhD· @DraMartinezLago · X·· 2 days agoScore90
Body
#ESMO26 💊 RAMIRIS | Phase II/III
👥 317 taxane-pretreated GEA
🔀 FOLFIRI+Ram vs Pac+Ram
❌ Co-primary endpoints not met
⏳ OS: 8.7 vs 7.5 mo (HR 0.95)
🎯 ORR: 25.3% vs 22.6%
✅ PFS: 5.5 vs 3.7 mo (HR 0.70; p=.003)
⚠️ G≥3 AEs: 70% vs 68%
💡 PFS benefit without OS improvement
@OncoAlert
816 views · 12 likes · 12 reposts · 0 replies
Conference abstracts
1017Pmatched by Developmental therapeutics
Phase 1 first-in-human (FIH) results of YL211, a c-Met targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors
https://esmocongress.esmo.orgNCT06110663NCT06110663matched by - **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
https://esmocongress.esmo.orgSource: Nieves Martinez Lago MD PhD · x.com